News

Infrastructure construction company Primoris (NYSE:PRIM) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 14.9% year on year to $1.74 billion. Its non-GAAP profit of $1.13 per share was 51.2% above analysts’ consensus estimates.

The operator of the OKX cryptocurrency exchange pleaded guilty on Monday to violating U.S. anti-money laundering laws and will pay nearly $505 million in fines and forfeited fees, the U.S. Department of Justice said. It entered its plea at a hearing before U.S. District Judge Katherine Polk Failla in Manhattan, who imposed the sentence. OKX is the world's fourth-ranked cryptocurrency spot exchange based on traffic, liquidity, trading volumes, and confidence in the legitimacy of reported trading volumes, according to CoinMarketCap.

Stocks are eyeing a rebound as investors eye tariff risks to Nvidia in the countdown to its earnings

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year revenue guidance of $850 million at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.03 per share was in line with analysts’ consensus estimates.

3D measurement and imaging company FARO (NASDAQ:FARO) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 5.4% year on year to $93.54 million. The company expects next quarter’s revenue to be around $81 million, close to analysts’ estimates. Its non-GAAP profit of $0.50 per share was 25% above analysts’ consensus estimates.

Video conferencing platform Zoom (NASDAQ:ZM) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 3.3% year on year to $1.18 billion. On the other hand, next quarter’s revenue guidance of $1.16 billion was less impressive, coming in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.41 per share was 4.6% above analysts’ consensus estimates.

Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q4 CY2024, with sales up 95.1% year on year to $481.1 million. On top of that, next quarter’s revenue guidance ($530 million at the midpoint) was surprisingly good and 4.6% above what analysts were expecting. Its GAAP profit of $0.11 per share was in line with analysts’ consensus estimates.

Home healthcare provider Addus HomeCare (NASDAQ:ADUS) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 7.5% year on year to $297.1 million. Its non-GAAP profit of $1.38 per share was 1.6% above analysts’ consensus estimates.

Palantir stock extended its slide over ongoing concerns of potential Pentagon budget cuts impacting the software company's revenue.

Online insurance comparison site EverQuote (NASDAQ:EVER) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 165% year on year to $147.5 million. On top of that, next quarter’s revenue guidance ($157.5 million at the midpoint) was surprisingly good and 14.3% above what analysts were expecting. Its GAAP profit of $0.33 per share was 67.9% above analysts’ consensus estimates.